We remain focused on continuing our growth and delivering exceptional value to both our customers and shareholders. Third quarter also achieved improved adjusted EBITDA results ... The development of ...
We anticipate a data readout from the STRIVE-ON trial in the first calendar quarter of 2025. NDA submission to the FDA is anticipated in the first half of calendar year 2025. Completion of the Company ...